Ipamorelin Patent Status and Generic Timeline

Original Patent History and Expiration

Novo Nordisk scientists first disclosed ipamorelin in a 1994 patent application that issued as US 5,506,364. The patent covered the pentapeptide sequence Aib-His-D-2Nal-D-Phe-Lys-NH2 and its use as a selective growth hormone secretagogue. A companion international filing (WO 95/17422) extended territorial coverage to Europe and Japan.

Under standard U.S. patent term calculations (20 years from the earliest filing date), composition-of-matter protection expired in 2014. No patent term extensions were granted because the compound never progressed through an FDA approval process that would qualify for Hatch-Waxman restoration under 35 U.S.C. § 156. European counterparts lapsed on comparable timelines.

Novo Nordisk published the definitive pharmacology study in 1998, demonstrating that ipamorelin produced dose-dependent GH release in swine and humans while sparing ACTH and cortisol axes [1]. Despite promising preclinical data, the company did not advance ipamorelin into Phase III trials. Internal pipeline documents from the late 1990s suggest a strategic pivot toward longer-acting GH analogs (eventually yielding somapacitan, approved in 2023).

The absence of follow-on method-of-use patents means no unexpired IP blocks exist for any therapeutic indication of ipamorelin in any jurisdiction as of May 2026.

Why No FDA-Approved Version Exists

The traditional drug development path requires a sponsor to file an Investigational New Drug (IND) application, conduct Phase I through III trials, and submit a New Drug Application (NDA). Ipamorelin never completed this sequence. Two factors explain the gap.

First, Novo Nordisk deprioritized the compound. Short-acting injectable GH secretagogues faced commercial headwinds against recombinant hGH products (Norditropin, Genotropin) that had established reimbursement pathways and prescriber familiarity. Second, ipamorelin's five-amino-acid structure made it relatively simple to synthesize, reducing the commercial moat any single manufacturer could build even with regulatory exclusivity.

Without an approved NDA, ipamorelin does not appear in the FDA's Orange Book. This creates a circular problem: generic manufacturers cannot file an Abbreviated New Drug Application (ANDA) because no Reference Listed Drug (RLD) exists against which to demonstrate bioequivalence.

The compound therefore occupies a category distinct from both branded drugs and traditional generics. It is neither.

The 503A Compounding Pathway

Ipamorelin acetate is currently available in the U.S. through Section 503A of the Federal Food, Drug, and Cosmetic Act. This section permits licensed pharmacies to compound medications for individual patients based on valid prescriptions, provided the bulk drug substance meets USP or compendial standards and is not on the FDA's withdrawn or unsuitable list.

The FDA maintains a Bulk Drug Substances list for 503A compounding. Peptides like ipamorelin have faced periodic regulatory scrutiny, particularly after the 2024 FDA guidance tightening oversight of compounded GLP-1 receptor agonists. As of mid-2026, ipamorelin acetate remains available for 503A compounding, though prescribers should monitor FDA enforcement actions quarterly.

Quality varies between compounding pharmacies. Physicians prescribing ipamorelin should verify that their pharmacy holds current state board licensure, performs third-party potency and sterility testing per USP <797> and USP <71> standards, and provides certificates of analysis (CoAs) with each batch. PCCA (Professional Compounding Centers of America) and similar organizations maintain supplier qualification programs that reduce adulteration risk.

Mechanism of Action: How Ipamorelin Works

Ipamorelin binds the growth hormone secretagogue receptor (GHS-R1a) on anterior pituitary somatotrophs. This G-protein-coupled receptor activation triggers intracellular calcium influx and subsequent GH vesicle exocytosis. The 1998 Raun study demonstrated that ipamorelin at doses of 0.01 to 0.1 mg/kg produced GH release comparable to GHRP-6 while generating no statistically significant increase in ACTH, cortisol, or prolactin [1].

This selectivity profile distinguishes ipamorelin from earlier GHRPs. GHRP-6, for example, activates ghrelin-mediated hunger pathways and stimulates cortisol at higher doses. GHRP-2 shows intermediate selectivity. Ipamorelin's narrow receptor engagement pattern (GHS-R1a agonism without meaningful off-target activation) explains its clinical popularity despite lack of formal regulatory approval.

The half-life is approximately 2 hours following subcutaneous injection, with peak GH elevation occurring at 30 to 40 minutes post-dose. Standard compounding protocols provide 200 to 300 mcg per injection, administered one to three times daily, typically timed to fasting states or pre-sleep windows when endogenous somatostatin tone is lowest.

A 2007 study by Johansen et al. explored ipamorelin's effects on postoperative ileus recovery, demonstrating accelerated bowel function restoration in patients receiving 0.03 mg/kg IV every 8 hours [2]. This remains the largest controlled human dataset for the compound.

Comparison to Other GH Secretagogues: Patent and Access Differences

Understanding ipamorelin's position requires comparison with related compounds. Sermorelin (GHRH 1-29) was FDA-approved as Geref Diagnostic but withdrawn from market in 2008 for commercial reasons. Its approval history means some compounding pharmacies reference legacy monograph standards. Tesamorelin (Egrifta) holds active patent protection and FDA approval for HIV-associated lipodystrophy; generic entry is not expected before 2028-2029 based on Orange Book patent listings.

CJC-1295 (with or without DAC modification) occupies a similar regulatory space to ipamorelin: never FDA-approved, no active patents, available through 503A compounding. The Modified GRF(1-29) variant (often called CJC-1295 no DAC) is frequently co-prescribed with ipamorelin in clinical protocols.

MK-677 (ibutamoren), an oral GHS-R1a agonist developed by Merck, completed Phase II trials but never received approval. Its patent protections have similarly lapsed. Unlike ipamorelin, MK-677's oral bioavailability created a gray-market supplement industry that complicates clinical sourcing.

The Endocrine Society's 2019 guidelines on GH therapy in adults do not specifically address compounded secretagogues, creating a gap between clinical practice patterns and formal society recommendations [3].

Regulatory Risk Factors for Future Access

Three regulatory vectors could alter ipamorelin's availability:

FDA nomination for the "Difficult to Compound" list. If FDA determines that ipamorelin presents demonstrable difficulties for compounding (stability, sterility, or dosing precision concerns), it could restrict 503A access. The agency has not signaled intent to nominate ipamorelin as of May 2026, but the 2024-2025 peptide compounding enforcement wave (targeting semaglutide and tirzepatide copies) demonstrated willingness to act rapidly.

503B outsourcing facility restrictions. Section 503B facilities compound without individual prescriptions for office use. FDA inspections of 503B facilities producing peptides increased 40% between 2023 and 2025 according to FDA inspection data. Facilities with repeated sterility failures have faced injunctions affecting peptide product lines broadly, not just the specific compound at issue.

State-level pharmacy board actions. Some state boards have independently restricted peptide compounding categories. Prescribers should verify jurisdiction-specific rules, particularly in states that have adopted more restrictive interpretations of 503A scope than the federal baseline.

Could a Sponsor Pursue FDA Approval?

Theoretically, any pharmaceutical company could file an IND for ipamorelin and pursue the NDA pathway. The compound's expired patent status means no composition-of-matter exclusivity would protect the sponsor's investment, but FDA offers alternative incentives.

New Chemical Entity (NCE) exclusivity provides 5 years of data protection from the approval date. If a sponsor obtained NDA approval for ipamorelin, no ANDA could reference that approval for 5 years regardless of patent status. This creates a commercial window, but the cost-benefit calculation is unfavorable: Phase III trials for a GH secretagogue indication would likely cost $150-300 million, while the target patient population already accesses the compound through compounding at $50-150 per month.

The 505(b)(2) pathway offers a potentially less expensive route. A sponsor could reference published literature (including the Raun 1998 and Johansen 2007 data) to support portions of the safety and efficacy package, conducting only bridging studies rather than full Phase III programs. No company has publicly disclosed pursuit of this strategy for ipamorelin.

Orphan Drug Designation could provide 7 years of market exclusivity for a specific rare disease indication. Ipamorelin's GH-releasing properties might support applications in adult GH deficiency subtypes or rare pediatric conditions, though the existing compounding access would likely undermine the "no satisfactory therapy" criterion required for orphan designation.

International Patent and Regulatory Status

Patent expiration timelines parallel the U.S. across major markets. European Patent EP 0 725 079 (corresponding to the Novo Nordisk filing) expired in 2014. Japanese and Australian equivalents lapsed on similar schedules.

Regulatory access differs substantially by jurisdiction. In Australia, ipamorelin falls under the Therapeutic Goods Administration's (TGA) compounding framework with similar provisions to U.S. 503A. The United Kingdom's MHRA permits specials manufacturing under Section 10 exemptions. In Canada, Health Canada's approach to compounded peptides is more restrictive; access typically requires Special Access Programme applications for individual patients.

No country has approved ipamorelin as a finished pharmaceutical product. The global status is uniformly: expired patents, no marketing authorization, compounding-only access where local law permits.

Clinical Implications for Prescribers

For physicians prescribing ipamorelin through compounding pharmacies, the patent-expired and unapproved status creates practical considerations. There is no FDA-required REMS program, no standardized package insert, and no post-marketing surveillance system collecting adverse event data. Prescribers bear full clinical responsibility for dosing decisions, monitoring protocols, and informed consent documentation.

The American Association of Clinical Endocrinology (AACE) has not issued specific guidance on compounded GH secretagogues [4]. Best practice recommendations from peptide therapy specialists suggest baseline and 3-month monitoring of IGF-1 levels, fasting glucose, and HbA1c, given GH's counter-regulatory effects on insulin sensitivity.

Prescribers should document the clinical rationale for choosing a compounded secretagogue over FDA-approved recombinant GH (e.g., Norditropin, Omnitrope) in the patient chart. Common documented reasons include patient preference for physiologic pulsatile GH release, cost differentials, or contraindications to supraphysiologic exogenous GH dosing.

IGF-1 target ranges of 200-300 ng/mL (age-adjusted upper tertile) represent the typical clinical goal, with dose titration based on 6-week lab reassessment cycles.